We also demonstrate that a DNA-only, less than 50-gene next-generation sequencing (sNGS) panel combined with ultra-rapid reflex testing via Idylla Genefusion assay provides a cost-effective testing schema for most lung cancer cases, thereby largely negating the need for upfront ALK and ROS1 fusion testing by FISH. This evidence concerns the gene ALK and lung cancer.